BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/26/2026 3:52:08 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-29 03:07 |
|
Peer-Review Started |
|
2025-12-29 03:11 |
|
First Decision by Editorial Office Director |
|
2025-12-31 08:19 |
|
Return for Revision |
|
2025-12-31 08:19 |
|
Revised |
|
2026-01-04 20:50 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-10 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-10 09:34 |
|
Articles in Press |
|
2026-02-10 09:34 |
|
Edit the Manuscript by Language Editor |
|
2026-02-13 22:01 |
|
Typeset the Manuscript |
|
2026-03-30 14:21 |
|
Publish the Manuscript Online |
|
2026-05-26 03:52 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Anti-obesity medications, the new frontiers, in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yasser Fouad, Wafaa A Abdelghany and Reem El Sheemy |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yasser Fouad, Department of Gastroenterology and Endemic Medicine, Faculty of Medicine, Minia University, El Omoumy Road, Minya 61511, Egypt. yasserfouad10@yahoo.com |
| Key Words |
Weight regain; Fibrosis; Sarcopenia; Glucagon-like peptide-1; Obesity; Metabolic associated steatohepatitis; Metabolic dysfunction-associated fatty liver disease |
| Core Tip |
Novel anti-obesity drugs, especially incretin-based treatments, successfully lower body weight and enhance metabolic dysfunction-associated fatty liver disease indicators like inflammation and steatosis. However, there are major obstacles that limit their long-term potential. These include the frequent recurrence of weight gain following discontinuation, significant side effects, high costs, risks of muscle loss, and inadequate data on fibrosis reversal. In addition to additional research and systemic healthcare reforms to address these limitations, a comprehensive, multidisciplinary approach is necessary to fully realize the potential of these medications for metabolic dysfunction-associated fatty liver disease. |
| Publish Date |
2026-05-26 03:52 |
| Citation |
Fouad Y, Abdelghany WA, El Sheemy R. Anti-obesity medications, the new frontiers, in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions. World J Hepatol 2026; 18(5): 118303 |
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i5/118303.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v18.i5.118303 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
